Showing results (71-80 of 179) with videos related to
Sort By:
Pageof 18
Oncotarget|August 29, 2015
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimensMarina K Baine, Gabriela Turcu, Christopher R Zito, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenibLucia Jilaveanu, Christopher Zito, Sandra J Lee, et al.Cancer Research|July 5, 2005
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive diseaseHarriet M Kluger, Dina Chelouche Lev, Yuval Kluger, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Spatially Informed Gene Signatures for Response to Immunotherapy in MelanomaThazin N Aung, Jonathan Warrell, Sandra Martinez-Morilla, et al.Journal for Immunotherapy of Cancer|June 16, 2019
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitorsWilliam Damsky, Lucia Jilaveanu, Noel Turner, et al.Cancer Immunology Research|December 25, 2015
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab TreatmentJustine V Cohen, Ahmed K Alomari, Alexander O Vortmeyer, et al.Proceedings of the National Academy of Sciences of the United States of America|January 30, 2008
Suppressor role of activating transcription factor 2 (ATF2) in skin cancerAnindita Bhoumik, Boris Fichtman, Charles Derossi, et al.Clinical Lung Cancer|December 12, 2018
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, et al.Journal of Neuro-Oncology|July 4, 2024
Patterns of brain metastases response to immunotherapy with pembrolizumabAmit Mahajan, Sarah L Goldberg, Sarah A Weiss, et al.British Journal of Cancer|January 20, 2017
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanomaAdil Daud, Harriet M Kluger, Razelle Kurzrock, et al.Pageof 18